144 related articles for article (PubMed ID: 15670547)
1. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years.
Robinson JG; Maheshwari N
Am J Cardiol; 2005 Feb; 95(3):373-8. PubMed ID: 15670547
[TBL] [Abstract][Full Text] [Related]
2. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
3. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
[TBL] [Abstract][Full Text] [Related]
4. [The best of epidemiology and cardiovascular prevention in 2006].
Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
[TBL] [Abstract][Full Text] [Related]
5. Statin alternatives or just placebo: an objective review of omega-3, red yeast rice and garlic in cardiovascular therapeutics.
Ong HT; Cheah JS
Chin Med J (Engl); 2008 Aug; 121(16):1588-94. PubMed ID: 18982874
[TBL] [Abstract][Full Text] [Related]
6. Secondary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA; Roth MT; Pieper JA
Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
8. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
[TBL] [Abstract][Full Text] [Related]
9. Secondary prevention for patients following a myocardial infarction: summary of NICE guidance.
Skinner JS; Cooper A; Feder GS;
Heart; 2007 Jul; 93(7):862-4. PubMed ID: 17569811
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population.
Mehta JL; Bursac Z; Hauer-Jensen M; Fort C; Fink LM
Am J Cardiol; 2006 Oct; 98(7):923-8. PubMed ID: 16996875
[TBL] [Abstract][Full Text] [Related]
11. Comparison of secondary prevention of heart disease in Europe: lifestyle getting worse, therapy getting better in Ireland.
Hall M; McGettigan M; O'Callaghan P; Graham I; Shelley E; Feely J
Ir Med J; 2002 Oct; 95(9):272-4. PubMed ID: 12469998
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk in patients with type 2 diabetes.
Shanks M; Holmes DT; Cermakova L; Frohlich J
CMAJ; 2005 Apr; 172(9):1160-1. PubMed ID: 15851694
[No Abstract] [Full Text] [Related]
13. [Conservative treatment of coronary heart disease--current options].
Desch S; Schuler G; Niebauer J
MMW Fortschr Med; 2005 Feb; 147(8):45-7. PubMed ID: 18437860
[TBL] [Abstract][Full Text] [Related]
14. Secondary prevention of CHD.
Nelson MR; Tonkin A
Aust Fam Physician; 2005 Jun; 34(6):433-40. PubMed ID: 15931401
[TBL] [Abstract][Full Text] [Related]
15. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
17. Secondary prevention of ischaemic cardiac events.
Gami A
Clin Evid; 2006 Jun; (15):195-228. PubMed ID: 16973010
[No Abstract] [Full Text] [Related]
18. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
19. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).
Dunkelgrun M; Boersma E; Schouten O; Koopman-van Gemert AW; van Poorten F; Bax JJ; Thomson IR; Poldermans D;
Ann Surg; 2009 Jun; 249(6):921-6. PubMed ID: 19474688
[TBL] [Abstract][Full Text] [Related]
20. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
